The GEO data showed that GPR50 expression was significantly upregulated in liver cancers (i.e., HCC) and downregulated in breast, cervical, esophagus, and lung cancers (Figure 1B; Table S1), which is in contrast with the expression patterns in the Oncomine database. Here, GPR50 is linked to liver cancer.